Charles Schwab Investment Management Inc. Takes Position in Astrana Health, Inc. (NASDAQ:ASTH)

Charles Schwab Investment Management Inc. purchased a new stake in Astrana Health, Inc. (NASDAQ:ASTH) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 447,796 shares of the company’s stock, valued at approximately $25,945,000. Charles Schwab Investment Management Inc. owned about 0.91% of Astrana Health as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ASTH. Central Pacific Bank Trust Division bought a new position in shares of Astrana Health in the 3rd quarter valued at $160,000. SG Americas Securities LLC bought a new stake in Astrana Health during the 3rd quarter worth $680,000. Granite Bay Wealth Management LLC bought a new stake in Astrana Health during the 3rd quarter worth $290,000. Handelsbanken Fonder AB bought a new stake in Astrana Health during the 3rd quarter worth $492,000. Finally, GAMMA Investing LLC bought a new stake in Astrana Health during the 3rd quarter worth $34,000. Institutional investors own 52.77% of the company’s stock.

Wall Street Analyst Weigh In

ASTH has been the topic of a number of research reports. BTIG Research boosted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Robert W. Baird boosted their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 price objective on the stock. Truist Financial boosted their price objective on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, KeyCorp initiated coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $65.17.

Astrana Health Stock Up 0.5 %

Shares of ASTH opened at $43.42 on Thursday. The company has a market capitalization of $2.44 billion, a PE ratio of 33.40, a PEG ratio of 2.09 and a beta of 1.13. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock’s 50-day moving average price is $52.05 and its two-hundred day moving average price is $48.05. Astrana Health, Inc. has a 12 month low of $32.32 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the previous year, the business earned $0.47 EPS. On average, analysts anticipate that Astrana Health, Inc. will post 1.16 EPS for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.